A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

Completed · Phase 2/Phase 3

Conditions studied: Multiple Myeloma

In brief

This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.

Key facts

Study ID

NCT00514371

Run by

Bristol-Myers Squibb

People needed

22

Starts

2007-08-01

Expected to finish

2009-02-01

Last updated by the study team

2015-12-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Good performance status
• Histologic evidence of multiple myeloma
• Have had at least three prior treatment regimens for multiple myeloma that included both bortezomib and lenalidomide
• No prior treatment with a heat shock 90 inhibitor or an investigational proteasome inhibitor
• No known infections of HAV, HBV, HCV, or HIV
• No chemotherapy, radiation therapy, or immune therapy for three weeks prior to enrollment.

Where it is running

• Local Institution — Berkeley, California, United States
• Local Institution — San Francisco, California, United States
• Local Institution — Augusta, Georgia, United States
• Local Institution — Baltimore, Maryland, United States
• Local Institution — Boston, Massachusetts, United States
• Local Institution — Omaha, Nebraska, United States
• Local Institution — New York, New York, United States
• Local Institution — New York, New York, United States
• Local Institution — Winston-Salem, North Carolina, United States
• Local Institution — Pittsburgh, Pennsylvania, United States
• Local Institution — Columbia, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.